This approach contributes to the correction of the acquired deficit of IL-2 in SLE and associates with an improvement of the impaired activity of the CD4+ T regulatory cells (Tregs), whose growth and survival depend on IL-2. The gene discussed is IL2; the disease is systemic lupus erythematosus.